Coronavirus Update: Sanofi And GSK’s Vaccine Suffers Setback

Plus: Pfizer On Track In US, But Needs More Time In India

 
• By Scrip Team

While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.  

Sanofi - GSK
The companies believe the vaccine could be authorized and ready for use by Q4 2021, approximately a six month delay to previous timelines.

More from Business

More from Scrip